CTOs on the Move

SeLux Diagnostics

www.seluxdx.com

 
SeLux Diagnostics is developing a Next Generation Phenotyping (NGP) platform that promises to transform infectious disease patient treatment by dramatically increasing the speed and accuracy with which targeted, personalized antibiotic therapies can be prescribed. Earlier, better-informed treatment decisions will save lives, improve patient outcomes, decrease hospital lengths of stay and hospital acquired infections, and help combat the global antibiotic resistance epidemic.
  • Number of Employees: 25-100
  • Annual Revenue: $0-1 Million
  • www.seluxdx.com
  • 56 Roland Street Suite 206
    Charlestown, MA USA 02129
  • Phone: 617.945.9383

Executives

Name Title Contact Details

Funding

SeLux Diagnostics raised $25M on 12/12/2018
SeLux Diagnostics raised $14.6M on 06/08/2021

Similar Companies

Jnana

Jnana was founded by leading academic scientists, drug developers and investors to develop medicines that transform the lives of patients by targeting the cell`s metabolic gates.

Provident Research

We specialize in recruiting clinical research talent and understand the hiring objectives of our Medical Device, Biotechnology, and Pharmaceutical clients.

Hometown Health Center

Hometown Health Center is a Schenectady, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Melinta

Melinta Therapeutics, Inc. (NASDAQ:MLNT) is the largest pure-play antibiotics company, dedicated to saving lives threatened by the global public health crisis of bacterial infections through the development and commercialization of novel antibiotics that provide new therapeutic solutions. Its four marketed products include Baxdela™ (delafloxacin), Vabomere™ (meropenem and vaborbactam), Orbactiv® (oritavancin), and Minocin® (minocycline) for Injection. It also has an extensive pipeline of preclinical and clinical-stage products representing many important classes of antibiotics, each targeted at a different segment of the anti-infective market. Together, this portfolio provides Melinta with the unique ability to provide providers and patients with a range of solutions that can meet the tremendous need for novel antibiotics treating serious infections.